Veraxa Biotech has entered a joint discovery partnership with OmniAb tp develop a bispecific antibody drug conjugate (bsADC) programme aimed at solid tumours.
The partnership unites OmniAb’s transgenic antibody discovery solutions with Veraxa’s ADC linker technology and conjugation expertise to propel next-generation therapeutic discovery.
Go deeper with GlobalData
Veraxa will commence a novel bsADC programme which addresses two target molecules in cancer medicine.
The company will leverage OmniAb’s transgenic antibody discovery solutions to procure high-quality human antibody leads, which will undergo natural optimisation via in vivo affinity maturation.
Veraxa will then set up the bsADC lead candidate by applying its proprietary linker technology and conjugation approach and will oversee the preclinical validation process.
The resulting bsADC programme will be co-owned by both companies, which will share future revenues from the programme’s further development, licensing and commercialisation efforts.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataVeraxa co-founder and CEO Christoph Antz stated: “This partnership brings together two highly complementary technologies to create a new class of bispecific ADCs. Bispecific ADCs represent a powerful opportunity to address difficult-to-treat solid tumours, and the collaboration fits squarely within our mission to drive innovation through targeted partnerships.
“Strategic collaborations will continue to be a mainstay in Veraxa’s pipeline growth strategy, and today’s announcement marks the second major initiative within the past six months, following our first radiopharmaceutical alliance late last year.”
Veraxa focuses on the discovery and development of antibody-based therapeutics, such as bispecific T cell engagers, bispecific ADCs and other formats.
The company is progressing its ADC pipeline and BiTAC (bi-targeted tumour-associated cytotoxicity) formats towards clinical development, leveraging transformative technologies and adhering to quality-by-design principles.
In April, Veraxa Biotech announced is set to go public in the US through a merger with Voyager Acquisition Corp, a healthcare special purpose acquisition company.
The deal is expected to close in the fourth quarter of 2025.
